PHARMACY

South Florida’s University of Miami Health System signs Walgreens collaboration agreement

BY Michael Johnsen

DEERFIELD, Ill. – Walgreens and the University of Miami Health System on Wednesday announced a collaboration focused on delivering coordinated clinical care and pharmacy excellence to patients across South Florida.

“Walgreens has been a trusted provider of pharmacy and other health care services to South Florida residents and those within the UM community for decades,” said Brad Fluegel, SVP and chief healthcare commercial market development officer at Walgreens. “This is a tremendous opportunity to work closely with the UM Health System to help ensure a true continuum of care, with our pharmacists playing an integral role as part of patients’ care teams. Forming deeper and more collaborative relationships with health systems is one of the ways in which we’re responding to the changing needs of both patients and our health care system.”

“This collaboration is an important step in UHealth’s commitment to improving the health of our community and access to our high quality clinicians,” stated Steven Altschuler, CEO of the University of Miami Health System. “We will provide a seamless and integrated health care experience for our patients regardless of where they receive their care across our University of Miami Health System.”

As part of the agreement, UHealth – the University of Miami Health System, will manage and provide all clinical services at 17 retail clinics within Walgreens stores in South Florida, including Miami-Dade, Broward and Palm Beach counties.
 
In addition, Walgreens will soon open pharmacies at three University of Miami Health System facilities, as its exclusive retail pharmacy provider. The new pharmacy at The Lennar Foundation Medical Center, UHealth’s state-of-the-art facility in Coral Gables, is planned to open Dec. 19. Walgreens retail pharmacies at Sylvester Comprehensive Cancer Center and University of Miami Hospital are expected to open in January.

Walgreens will also provide 90-day retail prescription benefits and specialty pharmacy services for the University’s employees and their families.

The 17 existing Walgreens Healthcare Clinics are planned to transition to the University of Miami Health System in the spring of 2017, at which time the clinics will become an extension of the UM Health System and be named UHealth Clinic – University of Miami Health System at Walgreens. Walgreens will continue to manage the retail clinics until that time.
 
UHealth Clinic at Walgreens will give consumers improved access to the transformative, research-based, personalized care provided by the University of Miami Health System. Staffed by UHealth’s expertly-trained nurse practitioners, the UHealth Clinic at Walgreens locations will operate seven days a week, including evenings, giving patients the option to receive a variety of health care services with or without an appointment.
 
Patients across South Florida will have access to affordable and conveniently located clinics for treating common illnesses and injuries as well as for follow up care for chronic diseases when appropriate.

Walgreens and the University of Miami Health System will also form a joint council to share best practices and experiences that aim to improve patient care, quality and satisfaction while reducing health care costs.
 
“Building from this start, the University and Walgreens intend to explore new approaches to further extend access to routine and specialty care, to improve patient health through enhanced pharmacy services, and to utilize innovative ways to reach patients when and where they would benefit,” added John Sory, UHealth’s chief executive of the UHealth Regional Alliance.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Omnicell completes Ateb acquisition

BY David Salazar
MOUNTAIN VIEW, Calif. — Omnicell on Wednesday announced that it had completed its acquisition of Ateb and its Canadian affiliate Ateb Canada. The company said the $41 million acquisition reinforces its commitment to improving patient care and outcomes by simplifying management of chronic conditions through increases access to adherence solutions. 
 
With the acquisition, Omnicell adds to its portfolio Ateb’s Time My Meds, an integrated medication synchronization program that uses the appointment-based model of medication refill pickup and consultation in an effort to improve adherence and health outcomes. It adds to Omnicell’s existing offerings, which include its SureMed medication adherence packaging and related automation. 
 
"By understanding the clinical and fiscal challenges these providers face, Omnicell now offers a portfolio of products and services that address the need for improved adherence across the continuum of care," Omnicell VP and GM medication adherence Troy Hilsenroth said. "We are excited about the strong potential of the combined entity, and to continue our mission of improving adherence and patient outcomes."
 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

BDSI names VP business development

BY David Salazar
RALEIGH, N.C. — BioDelivery Sciences International has named a new VP business development. BDSI announced Wednesday that it had chosen Peter Ginsberg, who has more than 25 years of business development and related experience, for the role. 
 
Ginsberg was most recently the head of business development for United Therapeutics, which he joined following his time at the North Carolina Biotechnology Center, where he was president of business and technology development. His other experience includes time overseeing acquisitions and licensing transactions as VP business development and strategic planning at SurModics. Ginsberg also spent 15 years working in healthcare investment. 
 
"We are very pleased to have Peter join BDSI given the depth and level of experience he brings as we look to enhance our focus on business development opportunities, particularly given the recent reacquisition of Belbuca," BDSI president and CEO Mark A. Sirgo said. "This hire will allow us to augment our efforts behind business opportunities for Belbuca and Bunavail both outside as well as inside the U.S."
 
The company recently reacquired the rights to Belbuca from Endo, which is shifting its U.S. branded business’s focus away from pain products. 
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?